NASDAQ:VIVE Viveve Medical (VIVE) Stock Price, News & Analysis → An utter travesty (From The Freeport Society) (Ad) Free VIVE Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume1,023 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsStock AnalysisChartCompetitorsFinancialsSEC FilingsTrends Get Viveve Medical alerts: Email Address Ad The Freeport SocietyAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. About Viveve Medical Stock (NASDAQ:VIVE)Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.Read More Ad The Freeport SocietyAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. VIVE Stock News HeadlinesApril 17, 2024 | finance.yahoo.com5-Alpha Reductase Deficiency Global Market Report 2024: A $1.94 Billion Projected Market in 2028April 15, 2024 | finance.yahoo.comInMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTLFebruary 23, 2024 | benzinga.comViveve Medical Stock (OTC:VIVE), Analyst Ratings, Price Targets, PredictionsJuly 29, 2023 | seekingalpha.comVIVE Viveve Medical, Inc.July 25, 2023 | finance.yahoo.comInMode Expands Women's Health and Wellness Market Footprint through Acquisition of Viveve PatentsJune 14, 2023 | uk.finance.yahoo.comVIVE - Viveve Medical, Inc.February 24, 2023 | finance.yahoo.comViveve Medical, Inc. (VIVE)January 17, 2023 | msn.comWhy Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionJanuary 17, 2023 | finanznachrichten.deViveve Medical, Inc.: Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceJanuary 17, 2023 | seekingalpha.comViveve crashes ~60% as company decides to delist, explore sale after trial failsJanuary 17, 2023 | finance.yahoo.comViveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceJanuary 17, 2023 | finance.yahoo.comViveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence TrialJanuary 17, 2023 | investorplace.comWhy Is Viveve Medical (VIVE) Stock Down 69% Today?December 29, 2022 | insidermonkey.comViveve Medical, Inc. (NASDAQ:VIVE) Q3 2022 Earnings Call TranscriptDecember 15, 2022 | finance.yahoo.comViveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits ConcludedDecember 1, 2022 | finanznachrichten.deViveve Medical, Inc.: Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceDecember 1, 2022 | finance.yahoo.comViveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceNovember 13, 2022 | finance.yahoo.comViveve Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 10, 2022 | finanznachrichten.deViveve Medical, Inc.: Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 10, 2022 | finance.yahoo.comViveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateOctober 27, 2022 | finance.yahoo.comViveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022October 25, 2022 | finance.yahoo.comGlobal Cosmetic Gynecology Market Report to 2027 - Featuring Alma Laser, Lutronic, Viveve Medical and Venus Concept Among OthersOctober 13, 2022 | forbes.comViveve MedicalOctober 4, 2022 | finanznachrichten.deViveve Medical, Inc.: Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceOctober 4, 2022 | finance.yahoo.comViveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceSee More Headlines Receive VIVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viveve Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today6/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:VIVE Previous SymbolOTCMKTS:PLCSD CUSIPN/A CIK879682 Webwww.viveve.com Phone(720) 696-8100Fax720-696-8199Employees47Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$6.43 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares10,720,000Free Float10,110,000Market CapN/A OptionableNot Optionable Beta0.44 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Jim B. Robbins (Age 60)Senior VP of Finance & Administration and Principal Accounting & Financial Officer Comp: $386.94kMs. Deborah Ann Jorn M.B.A. (Age 66)Senior Advisor to the CEO & Director Comp: $35kMr. Martin Kerber P.E.Vice President of Research, Development & OperationsMs. Jeannie SwindleSenior Director of Corporate CommunicationsMr. Jeff SinclairVice President of International SalesMr. Gary KaiserVice President of Global MarketingMs. Lori McMillanVice President of Human ResourcesMs. Suzon D. Lommel (Age 66)Senior Vice President of Regulatory & Quality Affairs More ExecutivesKey CompetitorsHologicNASDAQ:HOLXMedtronicNYSE:MDTMasimoNASDAQ:MASITransMedics GroupNASDAQ:TMDXIntegerNYSE:ITGRView All Competitors VIVE Stock Analysis - Frequently Asked Questions How were Viveve Medical's earnings last quarter? Viveve Medical, Inc. (NASDAQ:VIVE) announced its earnings results on Thursday, November, 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by $0.09. The business had revenue of $1.62 million for the quarter. During the same quarter in the previous year, the firm posted ($2.60) EPS. What other stocks do shareholders of Viveve Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Viveve Medical investors own include Corbus Pharmaceuticals (CRBP), Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), SCYNEXIS (SCYX), Western Digital (WDC), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Novavax (NVAX). When did Viveve Medical IPO? Viveve Medical (VIVE) raised $13 million in an initial public offering on Tuesday, June 14th 2016. The company issued 1,600,000 shares at $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager. How do I buy shares of Viveve Medical? Shares of VIVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIVE) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viveve Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viveve Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.